Patents by Inventor Sudhir Agrawal

Sudhir Agrawal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
    Publication number: 20090081198
    Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Application
    Filed: June 17, 2008
    Publication date: March 26, 2009
    Inventors: Ekambar Kandimalla, Daqing Wang, Yukui Li, Dong Yu, FuGang Zhu, Lakshmi Bhagat, Sudhir Agrawal
  • Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
    Publication number: 20090060898
    Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Application
    Filed: October 12, 2006
    Publication date: March 5, 2009
    Inventors: Ekambar R. Kandimalla, Daqing Wang, Yukui Li, Dong Yu, FuGang Zhu, Lakshmi Bhagat, Sudhir Agrawal
  • Immunostimulatory oligonucleotide multimers
    Patent number: 7498426
    Abstract: The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary.
    Type: Grant
    Filed: September 22, 2005
    Date of Patent: March 3, 2009
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Ekambar Kandimalla, Dong Yu
  • Immunostimulatory oligonucleotide multimers
    Patent number: 7498425
    Abstract: The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: March 3, 2009
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Ekambar Kandimalla, Dong Yu
  • TOLL LIKE RECEPTOR MODULATORS
    Publication number: 20090053148
    Abstract: The invention relates to TLR9 antagonist compounds and their therapeutic or prophylactic use. The invention provides novel immune regulatory oligonucleotides and immunomers as antagonist of TLRs and methods of use thereof. These immune regulatory oligonucleotides have unique sequences that suppress, without completely ablating, TLR-mediated signaling in response to a TLR ligand or TLR signaling agonist. The methods may have use in the prevention and treatment of autoimmunity, inflammation, inflammatory bowel disease, lupus, allergy, asthma, infection, sepsis, cancer and immunodeficiency.
    Type: Application
    Filed: August 15, 2008
    Publication date: February 26, 2009
    Inventors: Ekambar Kandimalla, Lakshmi Bhagat, Mallikarjuna Putta, Daqing Wang, Sudhir Agrawal
  • STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS
    Publication number: 20090053205
    Abstract: The invention relates to the therapeutic use of novel stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides novel RNA-based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.
    Type: Application
    Filed: July 7, 2008
    Publication date: February 26, 2009
    Inventors: Ekambar Kandimalla, Tao Lan, Daqing Wang, Lakshmi Bhagat, Sudhir Agrawal
  • NOVEL SYNTHETIC AGONISTS OF TLR9
    Publication number: 20090053206
    Abstract: The invention relates to synthetic chemical compositions that are useful for modulation of Toll-Like Receptor (TLR)-mediated immune responses. In particular, the invention relates to agonists of Toll-Like Receptor 9 (TLR9) that generate unique cytokine and chemokine profiles.
    Type: Application
    Filed: July 31, 2008
    Publication date: February 26, 2009
    Inventors: Ekambar R. Kandimalla, Mallikarjuna Putta, Daqing Wang, Dong Yu, Lakshmi Bhagat, Sudhir Agrawal
  • SHORT IMMUNOMODULATORY OLIGONUCLEOTIDES
    Publication number: 20090010938
    Abstract: The invention relates to modulation of the immune system. More particularly, the invention relates to modulating the immune system through the use of oligonucleotide-derived compounds. The invention provides immunostimulatory agents that are less expensive to make than existing immunostimulatory oligonucleotides. The immunostimulatory agents according to the invention can, in preferred embodiments, cause immune stimulation across species lines.
    Type: Application
    Filed: October 24, 2007
    Publication date: January 8, 2009
    Inventors: Sudhir Agrawal, Ekambar Kandimalla, Dong Yu, Lakshmi Bhagat
  • Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
    Patent number: 7470674
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunostimulatory oligonucleotides of the invention preferably comprise novel purines. The immunostimulatory oligonucleotides according to the invention further comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.
    Type: Grant
    Filed: November 7, 2005
    Date of Patent: December 30, 2008
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Dong Yu, Ekambar Kandimalla
  • SYNTHETIC AGONISTS OF TLR9
    Publication number: 20080292648
    Abstract: The invention provides novel oligonucleotide-based compounds that individually provide distinct immune response profiles through their interactions as agonists with TLR9. The TLR9 agonists according to the invention are characterized by specific and unique chemical modifications, which provide their distinctive immune response activation profiles.
    Type: Application
    Filed: December 12, 2007
    Publication date: November 27, 2008
    Inventors: Ekambar Kandimalla, Mallikarjuna Putta, Dong Yu, Lakshmi Bhagat, Daqing Wang, Sudhir Agrawal
  • Novel synthetic agonists of toll-like receptors containing CG dinucleotide modifications
    Publication number: 20080279785
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immune modulatory agents in immunotherapy applications. More particularly, the invention provides immune modulatory oligonucleotide compositions for use in methods for generating an immune response or for treating a patient in need of immune modulation. The immune modulatory oligonucleotides of the invention preferably comprise novel pyrimidines and purines.
    Type: Application
    Filed: December 19, 2006
    Publication date: November 13, 2008
    Inventors: Ekambar R. Kandimalla, Malikarjuna Reddy Putta, Yukui Li, Lakshmi Bhagat, FuGang Zhu, Sudhir Agrawal
  • Immunostimulatory oligonucleotide multimers
    Patent number: 7427405
    Abstract: The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: September 23, 2008
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Ekambar Kandimalla, Dong Yu
  • SYNERGISTIC TREATMENT OF CANCER USING IMMUNOMERS IN CONJUNCTION WITH CHEMOTHERAPEUTIC AGENTS
    Publication number: 20080206265
    Abstract: The invention relates to the therapeutic use of immunostimulatory oligonucleotides and/or immunomers in combination with chemotherapeutic agents to provide a synergistic therapeutic effect.
    Type: Application
    Filed: January 28, 2008
    Publication date: August 28, 2008
    Inventors: Ekambar R. Kandimalla, Sudhir Agrawal, Daqing Wang, Lakshmi Bhagat, Dong Yu
  • IMMUNOSTIMULATORY OLIGONUCLEOTIDE MULTIMERS
    Publication number: 20080193437
    Abstract: The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary.
    Type: Application
    Filed: October 23, 2007
    Publication date: August 14, 2008
    Inventors: Sudhir Agrawal, Ekambar Kandimalla, Dong Yu
  • Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5? ends
    Patent number: 7407944
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.
    Type: Grant
    Filed: August 25, 2004
    Date of Patent: August 5, 2008
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Ekambar R. Kandimalla, Dong Yu, Lakshmi Bhagat
  • Immunostimulatory oligonucleotide multimers
    Patent number: 7405285
    Abstract: The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary.
    Type: Grant
    Filed: September 22, 2005
    Date of Patent: July 29, 2008
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Ekambar Kandimalla, Dong Yu
  • STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8
    Publication number: 20080171712
    Abstract: The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.
    Type: Application
    Filed: April 6, 2007
    Publication date: July 17, 2008
    Inventors: Ekambar R. Kandimalla, Tao Lan, Yukui Li, Dong Yu, Daqing Wang, Mallikarjuna Reddy Putta, Sudhir Agrawal
  • Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
    Publication number: 20080152662
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.
    Type: Application
    Filed: October 3, 2007
    Publication date: June 26, 2008
    Inventors: Sudhir Agrawal, Ekambar R. Kandimalla, Dong Yu, Lakshmi Bhagat
  • IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
    Publication number: 20080089883
    Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Application
    Filed: May 3, 2007
    Publication date: April 17, 2008
    Inventors: Ekambar R. Kandimalla, Daqing Wang, Yukui Li, Dong Yu, FuGang Zhu, Lakshmi Bhagat, Sudhir Agrawal
  • Short immunomodulatory oligonucleotides
    Patent number: 7354907
    Abstract: The invention relates to modulation of the immune system. More particularly, the invention relates to modulating the immune system through the use of oligonucleotide-derived compounds. The invention provides immunostimulatory agents that are less expensive to make than existing immunostimulatory oligonucleotides. The immunostimulatory agents according to the invention can, in preferred embodiments, cause immune stimulation across species lines.
    Type: Grant
    Filed: February 7, 2003
    Date of Patent: April 8, 2008
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Ekambar R. Kandimalla, Dong Yu, Lakshmi Bhagat